Methods of treating restenosis

Abstract

Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel.

1 - 20 . (canceled)  
     
     
         21 . A stent coated with or containing an agent, the agent comprising a nucleic acid that encodes a SERCA protein.  
     
     
         22 . The stent of  claim 21 , wherein the agent is a nucleic acid that encodes SERCA1a, SERCA1b. SERCA2a, SERCA2b or SERCA3 polypeptide.  
     
     
         23 . The stent of  claim 21 , wherein the agent is packaged in a viral particle.  
     
     
         24 - 25 . (canceled)  
     
     
         26 . The stent of  claim 22 , wherein the agent is a nucleic acid that encodes SERCA2a polypeptide.  
     
     
         27 . The stent of  claim 21 , wherein the agent is packaged in a viral particle.  
     
     
         28 . The stent of  claim 27 , wherein the SERCA nucleic acid is a component of an adenovirus-based, adeno-associated virus-based, lentivirus-based or plasmid-based vector.  
     
     
         29 . The stent of  claim 28 , wherein the vector compromises the nucleic acid encoding SERCA operably linked to a viral or cardiac specific promoter.  
     
     
         30 . The stent of  claim 28 , wherein the vector compromises the nucleic acid encoding SERCA operably linked to an inducible promoter.  
     
     
         31 . The stent of  claim 21 , wherein the stent is coated with or contains the agent in an amount effective to prevent neointimal hyperplasia.  
     
     
         32 . A stent coated with or containing a nucleic acid that encodes a SERCA2a polypeptide, wherein the nucleic acid is a component of an adenovirus-based vector or adeno-associated virus-based vector.  
     
     
         33 . The stent of  claim 32 , wherein the nucleic acid encodes SERCA2a operably linked to a viral promoter.  
     
     
         34 . The stent of  claim 32 , wherein the nucleic acid encodes SERCA2a operably linked to an inducible promoter.  
     
     
         35 . The stent of  claim 32 , wherein the stent is coated with or contains the agent in an amount effective to prevent neointimal hyperplasia.  
     
     
         36 . A kit comprising a stent coated with, or containing, an agent comprising a nucleic acid that encodes a SERCA protein, and instructions for using the stent to treat restenosis.  
     
     
         37 . The kit of  claim 36 , wherein the agent is nucleic acid that encodes SERCA1a, SERCA1b, SERCA2a, SERCA2b or SERCA3 polypeptide.  
     
     
         38 . The kit of  claim 37 , wherein the agent is a nucleic acid that encodes SERCA2a polypeptide.  
     
     
         39 . The kit of  claim 36 , wherein the agent is packaged in a viral particle.  
     
     
         40 . The kit of  claim 39 , wherein the SERCA nucleic acid is a component of an adenovirus-based, adeno-associated virus-based, lentivirus-based or plasmid-based vector.  
     
     
         41 . The kit of  claim 38 , wherein the SERCA nucleic acid is a component of an adenovirus-based vector.  
     
     
         42 . The kit of  claim 38 , wherein the SERCA nucleic acid is a component of an adeno-associated virus-based vector.  
     
     
         43 . The kit of  claim 40 , wherein the vector compromises the nucleic acid encoding SERCA operably linked to a viral or cardiac specific promoter.  
     
     
         44 . The kit of  claim 40 , wherein the vector compromises the nucleic acid encoding SERCA operably linked to an inducible promoter.  
     
     
         45 . The kit of  claim 36 , wherein the stent is coated with or contains the agent in an amount effective to prevent neointimal hyperplasia